Sacubitril/Valsartan's impact on diastolic function in heart failure

Sacubitril/Valsartan enhances diastolic function in heart failure patients more effectively than existing treatments, promising improved care.

This review aimed to investigate the impact of novel therapy- Sacubitril/Valsartan on diastolic function among heart failure patients.

This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the PICO framework. The Embase, PubMed, Web of Science and Cochrane Library databases were explored. Inclusion and exclusion criteria were clearly defined, and an assessment of quality using the Cochrane Collaboration Risk of Bias tool was done. Fixed-effects and random-effects models were utilized for statistical analysis based on the level of heterogeneity between studies, evaluated using I2 statistics and Chi-square tests.

Out of 1129 publications screened, 8 studies, including randomized controlled trials and cohort studies from diverse global populations, met the inclusion criteria for the meta-analysis. Sacubitril/Valsartan treatment significantly reduced the echocardiographic parameter E/e' ratio by a mean difference of -1.38 and left atrial volume index (LAVi) by -4.62 compared to standard therapies.

Sacubitril/Valsartan demonstrates superior enhancement of diastolic function parameters in heart failure patients compared to existing therapies.